Highlights

  • Tilray Brands (NASDAQ:TLRY) gained about 27.5% during the session on December 16, 2025.
  • U.S. presidential comments on potential marijuana reclassification were linked to the stock’s move.
  • The broader market saw mixed performance on the same day, with major indexes diverging in direction.

On December 16, 2025, Tilray Brands (NASDAQ:TLRY) recorded a notable uptick in its share price, finishing the session up roughly 27.5% at USD 14.12. The move stood in contrast to broader market activity — the S&P 500 saw a slight decline while the Nasdaq Composite edged higher, signalling divergence in performance across major U.S. stock indexes.

Trading volume for TLRY was significantly elevated compared with recent averages, indicating heightened activity on the day. According to market data, millions of shares changed hands, markedly above the typical daily turnover observed in recent weeks.

Policy Commentary and Market Reaction

The session’s gains for TLRY were broadly connected to public comments from the U.S. presidential administration indicating that marijuana reclassification under federal law was being actively considered. In particular, remarks suggested a potential move to reclassify cannabis from Schedule I to Schedule III under federal controlled substances regulations, which would alter the current regulatory framework and could reduce tax burdens tied to federal classification rules.

While such a change would not equate to full legalization under federal law, it would represent a shift in how cannabis is categorised compared to other controlled substances. Debate around reclassification has drawn attention across the industry, with legal and regulatory observers noting the implications for tax treatment, banking access and research allowances.

Context Within Broader Market Activity

The performance of Tilray’s shares occurred against a backdrop of mixed results among U.S. equities on December 16. Key indexes including the S&P 500 and Dow Jones Industrial Average showed downward pressure, while the Nasdaq Composite registered modest gains, reflecting sector-level variation within the market.

Cannabis-related names beyond Tilray also experienced elevated activity in recent trading sessions, with several companies linked to broader discussions on federal policy adjustments seeing increased share price movement.